No Data
No Data
Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$16.62 From AU$13.94, Keeps at Buy
Telix Pharmaceuticals (ASX:TLX) has an average rating of buy and price targets ranging from AU$13.90 to AU$26, according to analysts polled by CapitalIQ. Price (AUD): $18.32, Change: $+0.17, Percent C
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF), CSL (OtherCMXHF) and Telix Pharmaceuticals Ltd. (OtherTLPPF)
Telix Completes TLX250-CDx (Zircaix) BLA Submission for Kidney Cancer Imaging
MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application
Up 80% in 2024, Here's Why the Telix Pharmaceuticals Share Price Is Marching Higher Again on Monday
The Telix Pharmaceuticals Ltd (ASX: TLX) share price has bounced back into the green today.
Telix Pharmaceuticals Target Price Raised 31% to A$19.00/Share by Bell Potter>TLX.AU
Telix Pharmaceuticals Target Price Raised 31% to A$19.00/Share by Bell Potter>TLX.AU
AU Evening Wrap: Australia Shares Rise 1%, Paring Recent Losses
Australia shares rise 1%, paring its recent losses but still slipping to a second straight weekly loss. Consumer stocks were among Friday's largest gainers, with travel-related companies, discretionary retailers and supermarkets all rising.
No Data